What is AKSO HEALTH GROUP's earnings per share (EPS)?

AKSO HEALTH GROUP (AHG) reported diluted earnings per share of $0.01 for fiscal year 2026. This represents a -93.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AKSO HEALTH GROUP Financials

AHG

FY2026 annual

Revenue $13.8M -6.4% YoY

Net Income -$18.7M +86.2% YoY

EPS (Diluted) $0.01 -93.8% YoY

Free Cash Flow -$12.8M -1350.9% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Mar 31, 2026 Reported Jul 23, 2026 Currency USD FYE March

AKSO HEALTH GROUP (AHG) reported $13.8M in revenue for fiscal year 2026, down 6.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AHG FY2026 2026-08-30

A balance sheet dominated by current assets masks operating economics with near-break-even gross margins and recurring cash outflow.

The apparent balance-sheet conservatism is not matched by operating liquidity: FY2026 total liabilities were only $8.7M against $189.6M of assets, yet the reported liquidity comparison was just 0.2 months of annual operating outflow. That combination indicates the large asset base is not equivalent to readily deployable cash, while operating cash flow swung from $1.2M in FY2025 to -$12.8M in FY2026.

Revenue fell 6.4% to $13.8M in FY2026, reducing scale without improving bottom-line economics. The gross margin was -0.1%, yet operating loss remained $20.7M; the pressure therefore sits below cost of revenue rather than in gross production alone.

Capital intensity is not the main explanation for cash use: FY2026 capital expenditures were only $2K, while investing cash flow was -$163.5M. Free cash flow reversed from $1.0M in FY2025 to -$12.8M, showing that reported earnings and cash generation moved together despite minimal conventional capital spending.

Financial Health Signals

Financial health score not available

AKSO HEALTH GROUP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Safe

49.81

AKSO HEALTH GROUP scores 49.81, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($734.0M) relative to total liabilities ($8.7M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/7

AKSO HEALTH GROUP passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

AKSO HEALTH GROUP reported a net loss of $18.7M while operations used $12.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$13.8M

YoY-6.4%

5Y CAGR+51.1%

AKSO HEALTH GROUP generated $13.8M in revenue in fiscal year 2026. This represents a decrease of 6.4% from the prior year.

EBITDA

-$18.3M

YoY+88.8%

AKSO HEALTH GROUP's EBITDA was -$18.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 88.8% from the prior year.

Net Income

-$18.7M

YoY+86.2%

AKSO HEALTH GROUP reported -$18.7M in net income in fiscal year 2026. This represents an increase of 86.2% from the prior year.

EPS (Diluted)

$0.01

YoY-93.8%

10Y CAGR-18.8%

AKSO HEALTH GROUP earned $0.01 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 93.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$12.8M

YoY-1350.9%

AKSO HEALTH GROUP recorded an outflow of $12.8M in free cash flow in fiscal year 2026, representing a cash shortfall after capex. This represents a decrease of 1350.9% from the prior year.

Cash & Debt

$171K

YoY-99.9%

5Y CAGR-59.2%

10Y CAGR-31.8%

AKSO HEALTH GROUP held $171K in cash as of fiscal year 2026; long-term debt is not reported for that period.

Dividends Per Share

Not reported for fiscal year 2026.

Shares Outstanding

Not reported for fiscal year 2026.

Margins & Returns

Gross Margin

-0.1%

YoY+1.8pp

5Y CAGR-100.1pp

AKSO HEALTH GROUP's gross margin was -0.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 1.8 percentage points from the prior year.

Return on Equity

-10.3%

YoY+57.5pp

5Y CAGR+191.3pp

10Y CAGR-35.6pp

AKSO HEALTH GROUP's ROE was -10.3% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 57.5 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

Capital Expenditures

$2K

YoY-98.9%

AKSO HEALTH GROUP invested $2K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 98.9% from the prior year.

R&D Spending

Not reported for fiscal year 2026.

Share Buybacks

Not reported for fiscal year 2026.

AHG Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AHG quarterly income statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Revenue	$13.8M-6.4%	$14.8M+512.1%	$2.4M-81.7%	$13.2M+119.7%	$6.0M+241.9%	$1.8M-74.6%	$6.9M+87.1%	$3.7M-96.6%	$107.3M+368.0%	$22.9M	N/A
Cost of Revenue	$13.8M-8.1%	$15.1M+557.0%	$2.3M-80.8%	$11.9M+120.8%	$5.4M+890.7%	$545K-47.3%	$1.0M-86.0%	$7.4M-12.9%	$8.5M+65.0%	$5.1M	N/A
Gross Profit	-$11K+96.0%	-$282K-330.5%	$122K-90.4%	$1.3M+109.7%	$605K-65.5%	$1.8M-74.6%	$6.9M+286.8%	-$3.7M-103.5%	$107.3M+368.0%	$22.9M+92.7%	$11.9M
R&D Expenses	N/A	N/A	N/A	N/A	$421K-4.6%	$441K+274.3%	$118K	$0-100.0%	$2.8M+79.7%	$1.6M+75.0%	$896K
SG&A Expenses	$4.0M+9.5%	$3.6M-57.6%	$8.6M-44.7%	$15.5M+481.7%	$2.7M+31.4%	$2.0M-90.1%	$20.5M+554.3%	$3.1M-46.2%	$5.8M+119.8%	$2.6M+70.2%	$1.6M
Operating Income	-$20.7M+87.6%	-$166.3M-1825.3%	-$8.6M+39.5%	-$14.3M-337.6%	-$3.3M+23.1%	-$4.2M+91.2%	-$48.1M-569.1%	-$7.2M-109.5%	$75.9M+665.4%	$9.9M+139.4%	$4.1M
Interest Expense	N/A	N/A	N/A	N/A	$804K-62.7%	$2.2M	N/A	N/A	$590K	N/A	N/A
Income Tax	-$2.0M+93.5%	-$30.8M-123363.8%	$25K+42.4%	$18K-81.1%	$93K-80.8%	$483K-1.4%	$490K-39.3%	$808K-92.7%	$11.0M+624.3%	$1.5M+142.3%	$628K
Net Income	-$18.7M+86.2%	-$135.0M-1327.0%	-$9.5M-595.5%	-$1.4M+91.9%	-$16.9M+51.6%	-$34.8M+51.1%	-$71.2M-1386.9%	$5.5M-91.6%	$65.5M+664.0%	$8.6M+142.2%	$3.5M
EPS (Diluted)	$0.01-93.8%	$0.16+128.6%	$0.07+450.0%	-$0.02+92.9%	-$0.28+60.6%	-$0.71+51.4%	-$1.46-1560.0%	$0.10-92.7%	$1.37+585.0%	$0.20+150.0%	$0.08

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).

AHG Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AHG quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Total Assets	$189.6M-11.8%	$215.0M+51.4%	$142.0M+594.1%	$20.5M-67.4%	$62.8M+23.9%	$50.7M-37.0%	$80.5M-53.6%	$173.3M+5.7%	$163.9M+477.4%	$28.4M	N/A
Current Assets	$189.5M-3.4%	$196.1M+38.1%	$142.0M+594.1%	$20.5M-67.4%	$62.8M+108.5%	$30.1M-42.1%	$52.0M-46.7%	$97.7M-40.1%	$163.1M	N/A	N/A
Cash & Equivalents	$171K-99.9%	$176.2M+106.9%	$85.2M+974.8%	$7.9M-57.0%	$18.4M+21.8%	$15.1M+126.9%	$6.7M-88.4%	$57.4M-56.7%	$132.6M+589.6%	$19.2M+146.0%	$7.8M
Inventory	$200K+5.2%	$190K-0.5%	$191K-88.7%	$1.7M-78.4%	$7.8M	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.3M+34.3%	$954K	N/A	$7.7M	N/A	N/A	N/A	$141K	$0	N/A	N/A
Goodwill	N/A	$10.8M-79.2%	$52.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.7M-44.9%	$15.8M+339.7%	$3.6M-69.1%	$11.6M-77.0%	$50.5M+51.2%	$33.4M+3.2%	$32.4M-30.8%	$46.8M+96.1%	$23.8M+388.9%	$4.9M	N/A
Current Liabilities	$8.7M-37.0%	$13.8M+284.3%	$3.6M-69.1%	$11.6M-77.0%	$50.5M+250.5%	$14.4M+16.6%	$12.4M-53.5%	$26.6M+11.4%	$23.8M	N/A	N/A
Total Equity	$180.9M-9.1%	$199.1M+43.9%	$138.4M+1485.8%	$8.7M-29.0%	$12.3M-28.9%	$17.3M-64.1%	$48.1M-62.0%	$126.5M-9.7%	$140.0M+495.8%	$23.5M+67.7%	$14.0M
Retained Earnings	-$217.6M-9.4%	-$198.9M-211.1%	-$63.9M-17.4%	-$54.5M-2.6%	-$53.1M-46.5%	-$36.3M-2436.1%	-$1.4M-102.0%	$69.8M-9.7%	$77.2M+556.9%	$11.8M	N/A

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Total Assets	$189.6M-10.6%	$212.0M-1.4%	$215.0M+0.9%	$212.9M+49.9%	$142.0M+741.3%	$16.9M-17.5%	$20.5M-2.1%	$20.9M
Current Assets	$189.5M+930.8%	$18.4M-90.6%	$196.1M+95.7%	$100.2M-29.4%	$142.0M+741.3%	$16.9M-17.5%	$20.5M-2.0%	$20.9M
Cash & Equivalents	$171K-98.5%	$11.1M-93.7%	$176.2M+92.9%	$91.4M+7.3%	$85.2M+824.6%	$9.2M+16.2%	$7.9M-20.7%	$10.0M
Inventory	$200K+3.2%	$194K+1.9%	$190K-3.3%	$197K+2.9%	$191K-84.4%	$1.2M-27.2%	$1.7M+87.5%	$900K
Accounts Receivable	$1.3M-59.6%	$3.2M+232.2%	$954K+133.7%	$408K	N/A	$5.8M-24.3%	$7.7M	N/A
Goodwill	N/A	$11.0M+1.9%	$10.8M-90.4%	$112.5M+115.9%	$52.1M	N/A	N/A	N/A
Total Liabilities	$8.7M-36.6%	$13.7M-13.1%	$15.8M+28.5%	$12.3M+242.2%	$3.6M-68.9%	$11.5M-0.6%	$11.6M+5.9%	$11.0M
Current Liabilities	$8.7M-27.5%	$12.0M-13.0%	$13.8M+12.9%	$12.2M+240.4%	$3.6M-68.9%	$11.5M-0.6%	$11.6M+5.9%	$11.0M
Total Equity	$180.9M-8.8%	$198.3M-0.4%	$199.1M-0.7%	$200.6M+45.0%	$138.4M+2549.0%	$5.2M-40.1%	$8.7M-12.0%	$9.9M
Retained Earnings	-$217.6M-8.7%	-$200.2M-0.6%	-$198.9M-208.3%	-$64.5M-0.9%	-$63.9M-10.4%	-$57.9M-6.3%	-$54.5M-4.1%	-$52.3M

Not reported in any period shown, so not listed: Long-Term Debt.

AHG Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

AHG quarterly cash flow statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Operating Cash Flow	-$12.8M-1186.6%	$1.2M-12.9%	$1.4M+141.5%	-$3.3M+62.3%	-$8.6M-185.8%	$10.1M+117.3%	-$58.3M-3266.6%	-$1.7M-102.0%	$87.7M+971.1%	$8.2M+16.6%	$7.0M
Capital Expenditures	$2K-98.9%	$154K	N/A	N/A	$5K	N/A	$200K+2539.8%	$8K-98.3%	$456K+58.5%	$288K+138.9%	$120K
Free Cash Flow	-$12.8M-1350.9%	$1.0M	N/A	N/A	-$8.6M	N/A	-$58.5M-3263.4%	-$1.7M-102.0%	$87.3M+1004.4%	$7.9M+14.4%	$6.9M
Investing Cash Flow	-$163.5M-54.3%	-$105.9M-93.6%	-$54.7M-396.3%	$18.5M+192.5%	-$20.0M-3015588.8%	-$662-100.0%	$12.8M+118.8%	-$68.1M-146.6%	-$27.6M-9499.4%	-$288K-138.9%	-$120K
Financing Cash Flow	$350K-99.8%	$195.9M+48.8%	$131.7M+578.5%	-$27.5M-179.1%	$34.8M+484.9%	-$9.0M-482.2%	-$1.6M-5183.7%	-$29K-100.1%	$47.5M+1008.0%	$4.3M+1662.9%	$243K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$19.5M	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$2.7M+102.0%	$1.3M	N/A	N/A	N/A

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23

Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.

AHG Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

AHG quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16
Gross Margin	-0.1%+1.8pp	-1.9%-7.0pp	5.1%-4.6pp	9.6%-0.5pp	10.1%-89.9pp	100.0%0.0pp	100.0%	-100.2%	100.0%0.0pp	100.0%	N/A
Operating Margin	-149.7%	-1125.4%	-357.8%	-108.2%	-54.3%	-241.7%	-695.7%	-194.6%	70.7%+27.5pp	43.3%	N/A
Net Margin	-135.0%	-913.4%	-391.8%	-10.3%	-280.9%	-1984.5%	-1029.7%	149.7%	61.1%+23.7pp	37.4%	N/A
Return on Equity	-10.3%+57.5pp	-67.8%-60.9pp	-6.8%+8.8pp	-15.6%+121.6pp	-137.2%+64.5pp	-201.6%-53.6pp	-148.0%-152.4pp	4.4%-42.4pp	46.8%+10.3pp	36.5%+11.2pp	25.3%
Return on Assets	-9.8%+52.9pp	-62.8%-56.1pp	-6.7%0.0pp	-6.7%+20.2pp	-26.8%+41.9pp	-68.7%+19.8pp	-88.5%-91.7pp	3.2%-36.8pp	40.0%+9.8pp	30.2%	N/A
Current Ratio	21.77+7.6x	14.20-25.3x	39.52+37.8x	1.76+0.5x	1.24-0.8x	2.09-2.1x	4.21+0.5x	3.68-3.2x	6.84	N/A	N/A
Debt-to-Equity	0.050.0x	0.08+0.1x	0.03-1.3x	1.33-2.8x	4.11+2.2x	1.93+1.3x	0.67+0.3x	0.37+0.2x	0.170.0x	0.21	N/A
FCF Margin	-92.5%-99.4pp	6.9%	N/A	N/A	-143.9%	N/A	-845.8%	-47.0%-128.4pp	81.4%+46.9pp	34.5%	N/A

Metric	Q4'26	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23
Current Ratio	21.77+20.2x	1.53-12.7x	14.20+6.0x	8.19-31.3x	39.52+38.1x	1.46-0.3x	1.76-0.1x	1.90
Debt-to-Equity	0.050.0x	0.070.0x	0.080.0x	0.060.0x	0.03-2.2x	2.21+0.9x	1.33+0.2x	1.11

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.

Similar Companies

Owens & Minor OMI

$216.6M

Henry Schein, Inc. HSIC

$10.0B

Quipt Home Medical Corp QIPT

$162.3M

111 YI

$30.4M

Inmode Ltd. INMD

$854.5M

Where AKSO HEALTH GROUP Ranks

Frequently Asked Questions

What is AKSO HEALTH GROUP's annual revenue?

AKSO HEALTH GROUP (AHG) reported $13.8M in total revenue for fiscal year 2026. This represents a -6.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AKSO HEALTH GROUP's revenue growing?

AKSO HEALTH GROUP (AHG) revenue declined by 6.4% year-over-year, from $14.8M to $13.8M in fiscal year 2026.

Is AKSO HEALTH GROUP profitable?

No, AKSO HEALTH GROUP (AHG) reported a net income of -$18.7M in fiscal year 2026.

What is AKSO HEALTH GROUP's EBITDA?

AKSO HEALTH GROUP (AHG) had EBITDA of -$18.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is AKSO HEALTH GROUP's gross margin?

AKSO HEALTH GROUP (AHG) had a gross margin of -0.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is AKSO HEALTH GROUP's return on equity (ROE)?

AKSO HEALTH GROUP (AHG) has a return on equity of -10.3% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is AKSO HEALTH GROUP's free cash flow?

AKSO HEALTH GROUP (AHG) recorded an outflow of $12.8M in free cash flow during fiscal year 2026. This represents a -1350.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AKSO HEALTH GROUP's operating cash flow?

AKSO HEALTH GROUP (AHG) recorded an outflow of $12.8M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are AKSO HEALTH GROUP's total assets?

AKSO HEALTH GROUP (AHG) had $189.6M in total assets as of fiscal year 2026, including both current and long-term assets.

What are AKSO HEALTH GROUP's capital expenditures?

AKSO HEALTH GROUP (AHG) invested $2K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

What is AKSO HEALTH GROUP's current ratio?

AKSO HEALTH GROUP (AHG) had a current ratio of 21.77 as of fiscal year 2026, which is generally considered healthy.

What is AKSO HEALTH GROUP's debt-to-equity ratio?

AKSO HEALTH GROUP (AHG) had a debt-to-equity ratio of 0.05 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AKSO HEALTH GROUP's return on assets (ROA)?

AKSO HEALTH GROUP (AHG) had a return on assets of -9.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

How does AKSO HEALTH GROUP's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, AKSO HEALTH GROUP (AHG) held $171K in cash, cash equivalents and investments, and reported an operating cash outflow of $12.8M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is AKSO HEALTH GROUP's Altman Z-Score?

AKSO HEALTH GROUP (AHG) has an Altman Z-Score of 49.81, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is AKSO HEALTH GROUP's Piotroski F-Score?

AKSO HEALTH GROUP (AHG) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AKSO HEALTH GROUP's earnings high quality?

AKSO HEALTH GROUP (AHG) reported a net loss of $18.7M while operations used $12.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.